Monosubstituted Maltosyl Cyclodextrins for the Potential Treatment of NPC
Niemann-Pick type C is a sever lysosomal storage disease, commonly refereed as ‘children’s Alzheimer’. There is no cure for it
Tag: Niemann Pick Disease
HPaCD against Alzheimer Disease
HP-beta-cyclodextrin (HPbCD) is currently in clinical trials against Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease (AD) and these trials
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
Presentation by Professor Caroline Hastings, MD, Chair of the Phase 3 Trappsol® Cyclo™ Program Steering Committee and the Global Principal Investigator
Brain uptake and distribution patterns of 2-hydroxypropyl-ß-cyclodextrin after intrathecal and intranasal administration
2-hydroxypropyl-ß-cyclodextrin (kleptose) is used for the treatment of Niemann–Pick disease. Kleptose crosses the blood–brain barrier poorly, in part because of
Cothreading of Unmodified and Monoazidated β-Mixed cyclodextrins in polyrotaxanes for Niemann Pick disease
To establish a method for the orthogonal chemical functionalization of β-cyclodextrin (β-CD)-based polyrotaxane (PRX), unmodified and monoazidated β-CDs (N3-β-CDs) were
Cyclo Therapeutics on Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase
Combined antioxidants and anti-inflammatory therapies fail to attenuate the early and late phases of cyclodextrin-induced cochlear damage and hearing loss
A major side effect of using high doses of HPβCD to treat Niemann Pick type C (NPC1) disease is sensorineural
Time- and frequency-dependent changes in acoustic startle reflex amplitude following cyclodextrin-induced outer and inner cell loss
The acoustic startle reflex (ASR) amplitude can be enhanced or suppressed by noise-induced hearing loss or age-related hearing loss; however,
Virtual Public Meeting: Endpoint Considerations to Facilitate Drug Development for Niemann-Pick Type C (NPC)
On January 24-25, 2022, the FDA and Duke-Margolis Center for Health Policy will host a virtual publicworkshop on endpoint considerations
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
Dec 9, 2021 – Dr. Hastings is a world-renowned Key Opinion Leader for Niemann-Pick Disease Type C1 and the first